F9 and hyperinsulinemic hypoglycemia, familial, 4: Recombinant Factor VIIa (rFVIIa, NovoSeven®, Novo Nordisk Inc, Princeton, NJ) is a potent clotting factor currently FDA-approved only for the control of bleeding in hemophiliacs with factor VIII (FVIII) or factor IX (FIX) inhibitors or patients with Factor VII deficiency.